Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: a possible mechanism for the antiarthritic activity of Au(I).

作者: Aida Chircorian , Amy M. Barrios

DOI: 10.1016/J.BMCL.2004.07.073

关键词: Enzyme inhibitorBiological activityRheumatoid arthritisMechanism of actionCathepsinBiochemistryEnzymeChemistryIn vivoProteases

摘要: Abstract Although Au(I) complexes have been used to treat rheumatoid arthritis for over 75 years, their mechanism of action is still poorly understood. A family enzymes responsible joint destruction in arthritis, the cathepsins, has discussed as a possible biological target Au(I). In this study, inhibition cathepsins by known drugs and related compounds was investigated. The tested inhibited cathepsin activity with IC50 values low 600 nM. More typical were 50–200 μM range. gold are not extremely potent inhibitors, it likely that biologically relevant given high concentrations serum joints patients undergoing chrysotherapy. While there multiple targets vivo, would provide protection against hallmark one antiarthritic activity.

参考文章(24)
K Hashimoto, C E Whitehurst, T Matsubara, K Hirohata, P E Lipsky, Immunomodulatory effects of therapeutic gold compounds. Gold sodium thiomalate inhibits the activity of T cell protein kinase C. Journal of Clinical Investigation. ,vol. 89, pp. 1839- 1848 ,(1992) , 10.1172/JCI115788
Daniel G. Baker, Joseph L. Rabinowitz, Current concepts in the treatment of rheumatoid arthritis. The Journal of Clinical Pharmacology. ,vol. 26, pp. 2- 21 ,(1986) , 10.1002/J.1552-4604.1986.TB02896.X
Simon P Pricker, Medical uses of gold compounds: Past, present and future Gold Bulletin. ,vol. 29, pp. 53- 60 ,(1996) , 10.1007/BF03215464
Kye-Im Jeon, Mi-Sun Byun, Dae-Myung Jue, Gold compound auranofin inhibits IκB kinase (IKK) by modifying Cys-179 of IKKβ subunit Experimental and Molecular Medicine. ,vol. 35, pp. 61- 66 ,(2003) , 10.1038/EMM.2003.9
C. Frank Shaw, Gold-Based Therapeutic Agents Chemical Reviews. ,vol. 99, pp. 2589- 2600 ,(1999) , 10.1021/CR980431O
David S. Pisetsky, Progress in the Treatment of Rheumatoid Arthritis JAMA. ,vol. 286, pp. 2787- 2790 ,(2001) , 10.1001/JAMA.286.22.2787
Rosanne M. Snyder, Christopher K. Mirabelli, Stanley T. Crooke, The cellular pharmacology of auranofin. Seminars in Arthritis and Rheumatism. ,vol. 17, pp. 71- 80 ,(1987) , 10.1016/0049-0172(87)90017-5
Antonio Baici, Annamaria Camus, Nazario Marsich, Interaction of the human leukocyte proteinases elastase and cathepsin G with gold, silver and copper compounds. Biochemical Pharmacology. ,vol. 33, pp. 1859- 1865 ,(1984) , 10.1016/0006-2952(84)90540-9
M. Chaffman, R.N. Brogden, R.C. Heel, T.M. Speight, G.S. Avery, Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis. Drugs. ,vol. 27, pp. 378- 424 ,(1984) , 10.2165/00003495-198427050-00002
Blaine M. Sutton, Elizabeth McGusty, Donald T. Walz, Michael J. DiMartino, Oral gold. Antiarthritic properties of alkylphosphinegold coordination complexes. Journal of Medicinal Chemistry. ,vol. 15, pp. 1095- 1098 ,(1972) , 10.1021/JM00281A001